

Supplementary material

Supplementary Table S1 Multiple regression model for change in high-density lipoprotein cholesterol between baseline and final visit.

Variables included in the regression model ^a	Partial regression coefficients		p
	$\beta\beta$	95% CI	
Initial model			
Gender (ref: female gender)	-4.16	-6.43 to -1.88	<0.001
Statins (ref: no)	6.49	2.51 to 10.46	0.001
ARBs (ref: no)	0.40	-1.82 to 2.61	0.724
Antiplatelets (ref: no)	1.47	-0.78 to 3.72	0.201
SRIs (ref: no)	2.72	0.01 to 5.43	0.049
Optimized final model			
Gender (reference: female)	-5.08	-7.19 to -2.97	<0.001
Statins (ref: no)	7.44	3.71 to 11.17	<0.001

ARBs: angiotensin receptor blockers; CI: confidence interval; ref: reference; SRIs: serotonin reuptake inhibitors.

^a p of the model: p<0.001. Adjusted R²=0.060 (the model explains 6.0%).

Supplementary Table S2 Multiple regression model for change in low-density lipoprotein cholesterol between baseline and final visits.

Variables included in the regression model ^a	Partial regression coefficients		p
	β	95% CI	
Initial model			
Age (continuous)	-0.02	-0.34 to 0.30	0.910
Statins (ref: no)	-48.56	-61.40 to -35.71	<0.001
ACEIs (ref: no)	-6.95	-15.71 to -1.82	0.120
ARBs (ref: no)	-6.20	-13.66 to 1.27	0.105
Oral antidiabetic drugs (ref: no)	-1.62	-9.67 to 6.43	0.695
Antiplatelets (ref: no)	-6.40	-14.70 to 1.91	0.214
CCBs (ref: no)	-3.23	-12.03 to 5.57	0.468
Allopurinol (ref: no)	-3.99	-11.51 to 3.53	0.317
Optimized final model			
Statins (ref: no)	-51.78	-64.28 to -39.28	<0.001
ACEIs (ref: no)	-12.56	-19.78 to -5.35	0.001
ARBs (ref: no)	-8.22	-15.33 to -1.11	0.024

ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CCBs: calcium channel blockers; CI: confidence interval; ref: reference; SRIs: serotonin reuptake inhibitors.

^a p of the model: p<0.001. Adjusted R²=0.210 (the model explains 21%).